Kanser ve Genetik
Özet
Kanser, hücrelerin kontrolsüz şekilde çoğalmasına ve çevre dokulara yayılmasına neden olan genetik ve çevresel faktörlerin etkileşimiyle ortaya çıkan kompleks bir hastalıktır. Kanser gelişimi, hücre döngüsünü düzenleyen genetik mekanizmalardaki bozukluklarla yakından ilişkilidir. Proto- onkogenlerin aktivasyonu, tümör baskılayıcı genlerin inaktivasyonu ve DNA onarım mekanizmalarındaki bozukluklar kanser oluşumuna zemin hazırlar. Çevresel faktörler (iyonize radyasyon, ultraviyole ışınlar, kimyasal, viral ajanlar, kronik enfeksiyonlar gibi) ve kalıtsal mutasyonlar bu süreçte kritik rol oynar. Kanserin ilerleyen aşamalarında tamir mekanizmaları, telomer kısalması ve apoptoz mekanizmasının devre dışı bırakılması gibi olaylar hastalığın şiddetini artırarak metastaza yönlendirebilir. Kromozomal translokasyonlar, gen amplifikasyonu ve epigenetik değişiklikler de kanser gelişimine katkıda bulunur. Günümüzde kanserin genetik temelleri daha iyi anlaşılmakta ve bireyselleştirilmiş tedavi yaklaşımları geliştirilmektedir. Genetik ve moleküler biyoloji alanındaki ilerlemeler sayesinde, hedefe yönelik tedaviler, immünoterapiler ve genetik testler ile daha etkili kanser yönetimi mümkün hale gelmektedir.
Cancer is a complex disease caused by the interaction of genetic and environmental factors that cause cells to proliferate uncontrollably and spread to surrounding tissues. Cancer development is closely linked to defects in the genetic mechanisms that regulate the cell cycle. Activation of proto- oncogenes, inactivation of tumor suppressor genes, and defects in DNA repair mechanisms predispose to cancer formation. Environmental factors (such as ionizing radiation, ultraviolet rays, chemical, viral agents, chronic infections) and inherited mutations play a critical role in this process. In the later stages of cancer, events such as repair mechanisms, telomere shortening, and deactivation of the apoptosis mechanism may increase the severity of the disease and lead to metastasis. Chromosomal translocations, gene amplification, and epigenetic changes also contribute to cancer development. Today, the genetic basis of cancer is better understood, and individualized treatment approaches are being developed. Advances in genetics and molecular biology are enabling more effective cancer management through targeted therapies, immunotherapies, and genetic testing.
Referanslar
Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular biology of the cell (2nd edition), New York: Garland Science; 2002.
Weinberg WA. The Biology of Cancer. (Second Edition). United States of America: Garland Science; 2014.
Khan M, Pelengaris S. The Molecular Biology of Cancer: A Bridge from Bench to Bedside 2nd edition. Pelengaris S, Khan M (ed.) Overview of Cancer Biology. Oxford: Wiley-Blackwell Publishing Ltd; 2013. p. 11–16.
Pelengaris S, Khan M. The Molecular Biology of Cancer: A Bridge from Bench to Bedside 2nd edition. Pelengaris S, Khan M (ed) Nature and Nurture in Oncogenesis. Oxford: Wiley-Blackwell Publishing Ltd; 2013. p. 78–95
Weber TK. Genetic and cancer. Clark S (ed.). A Guide to Cancer Genetics in Clinical Practice. Annals of First edition. Harley [England] : TFM Publishing. 2009. p. 15–18.
Yokus B. ve Ülker D.Ü..: Kanser Biyokimyası. Dicle Üniv Vet Fak Derg 2012: 1(2): 7–18
Pelengaris S, Khan M. The Molecular Biology of Cancer: A Bridge from Bench to Bedside 2nd edition. Pelengaris S, Khan M (ed) Oncogenesis. Oxford: Wiley-Blackwell Publishing Ltd; 2013. p. 188–189.
Pelengaris S, Khan M. The Molecular Biology of Cancer: A Bridge from Bench to Bedside 2nd edition. Pelengaris S, Khan M (ed) Tumor suppressors. Oxford: Wiley-Blackwell Publishing Ltd; 2013. p. 239.
Cooper, G.M. Oncogenes. In: The Cell: A Molecular Approach. 2nd ed; Sinauer Associates, Sunderland (MA), USA, 2000.
Puiu, AG, Lupu O, Preda M et al. Comparative Analysis Between Cellular Oncogenes and Viral Oncogenes. Biointerface Research in Applied Chemistry. 2020;11: 9939-9951. doi: 10.33263/BRIAC113.99399951
Zheng, Z.-M. Viral Oncogenes, Noncoding RNAs, and RNA Splicing in Human Tumor Viruses. International Journal of Biological Sciences. 2010;6: 730-755, doi.org/10.7150/ijbs.6.730.
Patel KR, Patel HD. p53: An Attractive Therapeutic Target for Cancer. Current medicinal chemistry. 2020;27(22): 3706–3734. doi.org/10.2174/1573406415666190621094704.
Correia C, Schneider PA, Dai H et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood, 2015;125(4): 658–667. doi.org/10.1182/blood-2014-04-571786
Park YH, Shin HT, Jung HH, et al. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer. Oncotarget. 2015;6(31): 32027–32038. doi.org/10.18632/oncotarget.5184.
Xu-Monette Z, Deng Q, Manyam G et al. MYC mutation profiling and prognostic significance in de novo diffuse large B-cell lymphoma. Clinical Cancer Research, 2016;22(14): 3593–3605. doi.org/10.1158/1078-0432.CCR-15-2296.
Downward J. Targeting RAS signalling pathways in cancer therapy. Nature Reviews Cancer. 2003:3(1); 11–22. doi.org/10.1038/nrc969.
Chiu IM, Reddy EP, Givol D et al. Nucleotide sequence analysis identifies the human c-sis proto-oncogene as a structural gene for platelet-derived growth factor. Cell. 1984;37(1): 123–129. doi.org/10.1016/0092-8674(84)90307-6
Aoki K, Taketo MM. Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. Journal of Cell Science. 2007;120(Pt 19): 3327–3335.doi.org/10.1242/jcs.03485.
Mersch J, Jackson MA, Park M et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121(2): 269–275. doi.org/10.1002/cncr.29041.
He XS, Su Q, Chen ZC et al. Expression, deletion [was deleton] and mutation of p16 gene in human gastric cancer. World Journal of Gastroenterology. 2001;7(4): 515–521. doi.org/10.3748/wjg.v7.i4.515.
Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nature Reviews Cancer, 2009;9(6): 400–414. doi.org/10.1038/nrc2657.
Muller PA, Vousden KH. p53 mutations in cancer. Nature Cell Biology. 2013;15(1): 2–8. doi.org/10.1038/ncb2641.
de Voer RM, Hahn MM, Mensenkamp AR et al. Deleterious germline BLM mutations and the risk for early-onset colorectal cancer. Scientific Reports. 2015; 5:14060. doi.org/10.1038/srep14060
Soufir N, Ged C, Bourillon A et al. A prevalent mutation with founder effect in xeroderma pigmentosum group C from north Africa. Journal of Investigative Dermatology. 2010;130(6): 1537–1542. doi.org/10.1038/jid.2009.409.
Pelengaris S, Khan M. The Molecular Biology of Cancer: A Bridge from Bench to Bedside 2nd edition. Pelengaris S, Khan M (ed). Growth signaling pathways and targeted treatment. Oxford: Wiley-Blackwell Publishing Ltd; 2013. p. 146.
Pelengaris S, Khan M. The Molecular Biology of Cancer: A Bridge from Bench to Bedside 2nd edition. Pelengaris S, Khan M (ed). DNA replication and the cell cycle. Oxford: Wiley-Blackwell Publishing Ltd; 2013. p. 111.
Khan M. The Molecular Biology of Cancer: A Bridge from Bench to Bedside 2nd edition. Pelengaris S, Khan M (ed). Genetic Instability Chromosomes and Repair. Oxford: Wiley-Blackwell Publishing Ltd; 2013. p. 314–315.
Blasco MA, Khan M. The Molecular Biology of Cancer: A Bridge from Bench to Bedside 2nd edition. Pelengaris S, Khan M (ed). Senescence, Telomeres, and Cancer Stem Cells. Oxford: Wiley-Blackwell Publishing Ltd; 2013. p. 294–295.
Pelengaris S, Khan M. The Molecular Biology of Cancer: A Bridge from Bench to Bedside 2nd edition. Pelengaris S, Khan M (ed). Cell death. Oxford: Wiley-Blackwell Publishing Ltd; 2013. p. 266.
KEGG: Kyoto Encyclopedia of Genes and Genomes. Cancer. 2025. (27.02.2025 tarihinde https://www.genome.jp/entry/map05200 adresinden ulaşılmıştır).
Wu K, Rodrigues L, Post G, et al. Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs. NPJ precision oncology, 2023;7(1): 8. doi.org/10.1038/s41698-023-00346-3.
Sakthikumar S, Warrier M, Whitley D, et al. Genomic analysis across 53 canine cancer types reveals novel mutations and high clinical actionability potential. Veterinary and comparative oncology, 2024;22(1):30–41. doi.org/10.1111/vco.12944.
Chon E, Sakthikumar S, Tang M, et al. Novel genomic prognostic biomarkers for dogs with cancer. Journal of veterinary internal medicine, 2023;37(6): 2410–2421. doi.org/10.1111/jvim.16893.
Kang JT, Ryu J, Cho B et al. Generation of RUNX3 knockout pigs using CRISPR/Cas9-mediated gene targeting. Reproductive Domestic Animals. 2016;51(6): 970–978. doi: 10.1111/rda.12775.
Rodrigues L, Watson J, Feng Y et al. Shared hotspot mutations in oncogenes position dogs as an unparalleled comparative model for precision therapeutics. Scientific Reports. 2023;13(1): 10935. doi: 10.1038/s41598-023-37505-2.
Arendt ML, Sakthikumar S, Melin M et al. PIK3CA is recurrently mutated in canine mammary tumors, similarly to in human mammary neoplasia. Scientific Reports. 2023;13(1): 632. doi: 10.1038/s41598-023-27664-7.
Alsaihati BA, Ho KL, Watson J et al. Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds. Nature Communications. 2021;12: 4670. doi.org/10.1038/s41467-021-24836-9.
OMIA - Online Mendelian Inheritance in Animals. Cancer. 2025. (27.02.2025 tarihinde https://omia.org/ adresinden ulaşılmıştır).
Sheikh E, Tran T, Vranic S et al. Role and significance of c-KIT receptor tyrosine kinase in cancer: A review. Bosnian journal of basic medical sciences. 2022;22(5): 683–698. doi.org/10.17305/bjbms.2021.7399.
Dray BK, Raveendran M, Harris RA et al. Mismatch repair gene mutations lead to lynch syndrome colorectal cancer in rhesus macaques. Genes Cancer. 2018;9: 142–152. doi: 10.18632/genesandcancer.170.
Chen L, Bellone RR, Wang Y et al. A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma. DNA Repair. 2021;97: 103022. doi.org/10.1016/j.dnarep.2020.103022.
Ciccarelli S, Di Bello A, Valastro C et al. Unilateral renal cystadenocarcinoma and nodular dermatofibrosis in a mixed-breed dog carrying a FLCN gene mutation. Veterinary Dermatology 2019, doi.org/10.1111/vde.12719.
